Search DSIP side effects and you get short, soothing lists. The published file behind them is one human report from 1988 and animal work in which mistimed dosing killed 100% of the rats.
The short answer. No controlled human trial has reported DSIP adverse events, so published side effect lists have no source.
- The only human data point commonly cited is Iyer and McCann, 1988, in alcohol-withdrawal patients.
- Russian 2021 rat work found protection only when the peptide was given at reperfusion.
- Pilot dosing during the ischemic event was reported to kill 100% of animals.
DSIP has no modern controlled safety trial in humans. The human record is one small report from 1988. It gave 120 mcg/kg for seven days to withdrawal patients. Rat work found a timing problem, not a dose problem. Dosing during the stroke killed 100% of animals. An empty side effect list is not a clean one.
What are the side effects of DSIP?
Nobody has published one. There is no adverse event table for DSIP from a controlled human trial, because there is no controlled human trial. The lists circulating on vendor pages are not traceable to a study we could find.
That is the honest answer, and it is not the same as saying the peptide is safe. It means the measurement was never made.
DSIP is a 9-amino-acid peptide pulled from rabbit brain blood in 1977 by Schoenenberger and Monnier. Nearly fifty years later, the number of Western randomized trials reporting its safety in people is zero.
An empty side effect list can mean two very different things. It can mean a drug was tested hard and came back clean. Or it can mean nobody looked. For DSIP, nobody looked.
The background on what the compound is, and is not, sits in the DSIP complete guide.
The one human report, from 1988
The single human data point people keep citing is Iyer and McCann, published in the Annals of the New York Academy of Sciences in 1988. It looked at cortisol in alcohol-withdrawal patients.
The report describes giving 120 mcg/kg of DSIP for 7 days. That is what was administered in that setting. It is a description of an old study, not a plan for anyone.
- The group was small. It was a short conference-era report, not a powered trial.
- The population was unusual. Alcohol withdrawal is a state with its own cortisol surge and its own risks.
- The endpoint was a hormone, not harm. The paper is cited for cortisol suppression, not for a safety profile.
- It is nearly forty years old. Nothing in the modern Western literature has replicated it.
We take that paper apart in the DSIP stress and cortisol page. One small report is the entire human HPA-axis file.
The finding marketing leaves out: 100% animal mortality
The most serious signal in the DSIP literature is not a side effect in a person. It is a timing effect in rats.
Russian groups led by Tukhovskaya published two 2021 papers on DSIP and DSIP-like peptides in stroke and heart attack models. The headline results were protective. The protection depended on when the peptide went in.
DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl/6 and Reduces Myocardial Infarction in SD Rats When Administered during Reperfusion.
Tukhovskaya et al., Biomedicines, 2021 (paper title)Read the last four words again. The benefit was tied to dosing at reperfusion, the moment blood flow returns. In pilot work where the peptide was given during the ischemic event instead, reported animal mortality reached 100%.
That is a 100% animal death rate from the same compound sold as a gentle sleep aid. The difference was not the amount. It was the clock.
The companion paper in Molecules reported motor recovery in SD rats after focal stroke. Both are rodent studies. Neither tells you what the peptide does in a healthy person, and neither was designed to.
More on how that work is framed in the DSIP benefits page.
DSIP
The compound discussed here, supplied as a research compound with a certificate of analysis matched to the lot.
No receptor means no predictable risk profile
Most drugs let you guess at side effects before you test them. You know the target, you know where the target sits in the body, and you can predict what else will be hit.
DSIP does not offer that. Inoue's 2020 review of sleep substances leaves the receptor question open. Five decades after isolation, no DSIP receptor has been identified.
The review literature instead describes activity spread across at least 4 neurotransmitter systems. DSIP-like material has also been reported in human blood at around 75 ng/mL, with no settled account of what it does there.
So the risk model is blank at both ends. No target, and no human exposure data. The delta wave mechanism page covers why the sleep claim itself is contested.
What a safety record usually contains
It helps to see the gap laid out against what a reviewed medicine carries.
| Safety evidence type | Approved medicine | DSIP |
|---|---|---|
| Phase I human safety trial | Required | None published |
| Adverse event tables with a control arm | Required | None published |
| Identified receptor or target | Usually defined | Not found in five decades |
| Long-term human exposure data | Post-marketing registries | None |
| Animal lethality signal | Characterized in tox studies | 100% mortality in one mistimed pilot |
The newest work does not close that gap either. A 2024 paper in Frontiers in Pharmacology tested a DSIP fusion peptide in chemically induced insomnia, in mice.
Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models.
Mu et al., Frontiers in Pharmacology, 2024 (paper title)That is the state of the art in 2024: a mouse model, a chemical insomnia inducer, and a fusion construct that is not the plain peptide.
What you can actually verify before anything else
Since the pharmacology file is empty, the only things left to check are the ones about the vial in front of you. Those are documents, and documents can be read.
- Identity and purity. Ask what the certificate of analysis actually tests, and whether it matches the lot number on the vial.
- Handling. Peptide degradation is a quality question, and storage temperature is the usual failure point.
- Legal status. Research-use rules differ by country and by compound. See are peptides legal.
None of that makes DSIP safe. It only tells you what is in the container. The question of what the contents do in a human body has not been answered in 48 years.
DSIP
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- No controlled human trial has reported DSIP adverse events, so published side effect lists have no source.
- The only human data point commonly cited is Iyer and McCann, 1988, in alcohol-withdrawal patients.
- Russian 2021 rat work found protection only when the peptide was given at reperfusion.
- Pilot dosing during the ischemic event was reported to kill 100% of animals.
- No DSIP receptor has been identified in roughly five decades, so risks cannot be predicted from mechanism.
- The 2024 state of the art is a fusion peptide in chemically induced insomnia in mice.
What we're watching
Watch for the first registered, controlled human trial of plain DSIP with a published adverse event table. Until one exists, every side effect list online is a guess dressed as a record.
Frequently asked questions
Does DSIP have known side effects?
None have been established in a controlled human trial, because no such trial has been published. Vendor side effect lists are not traceable to a study. Absence of reported harm is not evidence of safety here; it is evidence that nobody measured.
Is DSIP dangerous?
Unknown in humans. The one hard warning in the literature is animal data: Russian 2021 rat work reported 100% mortality in pilot experiments where the peptide was given during the ischemic event rather than at reperfusion. That was a timing effect in a disease model, not a healthy-subject finding.
How much DSIP has been given to humans in a study?
The 1988 report by Iyer and McCann describes 120 mcg/kg for 7 days in alcohol-withdrawal patients. That is a description of one old study in a specific clinical population. It is not a schedule and nothing has replicated it.
Does DSIP affect cortisol or hormones long term?
No long-term human hormone data exists. The cortisol claim rests on the single 1988 withdrawal report. Our DSIP stress and cortisol page sets out why that one paper cannot support a general stress claim.
Why is there no safety data after fifty years?
DSIP was isolated in 1977 and never completed Western clinical development. No receptor was found, the sleep effect was never confirmed in humans, and modern work shifted to stroke and heart injury models in rats. The safety file stayed empty.
References
- Tukhovskaya, E. A., Shaykhutdinova, E. R., Ismailova, A. M., et al. (2021). DSIP-Like KND Peptide Reduces Brain Infarction in C57Bl/6 and Reduces Myocardial Infarction in SD Rats When Administered during Reperfusion. Biomedicines, 9(4), 407. https://doi.org/10.3390/biomedicines9040407
- Tukhovskaya, E. A., Ismailova, A. M., Shaykhutdinova, E. R., et al. (2021). Delta Sleep-Inducing Peptide Recovers Motor Function in SD Rats after Focal Stroke. Molecules, 26(17), 5173. https://doi.org/10.3390/molecules26175173
- Mu, X., Qu, L., Yin, L., Wang, L., Liu, X., & Liu, D. (2024). Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models. Frontiers in Pharmacology, 15, 1439536. https://doi.org/10.3389/fphar.2024.1439536
- Schoenenberger, G. A., & Monnier, M. (1977). Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences USA, 74(3), 1282–1286. (Original DSIP isolation paper; cited here for historical context.) https://doi.org/10.1073/pnas.74.3.1282
- Inoué, S. (2020). Delta-sleep-inducing peptide and its derivatives. In Biology of Sleep Substances (chapter 3). CRC Press. (Modern review of DSIP physiology and the unresolved receptor question; readers should treat the 2020–2026 PubMed-indexed literature, including Tukhovskaya 2021 and Mu 2024 above, as the relevant modern evidence base for the mechanism questions discussed here.) https://doi.org/10.1201/9781003068228-3
- Iyer, K. S., & McCann, S. M. (1988). Delta sleep inducing peptide (DSIP) suppression of cortisol in alcohol-withdrawal patients. Annals of the New York Academy of Sciences, 525, 530–532. [Foundational early human data point cited across the DSIP HPA-axis literature.] https://doi.org/10.1159/isbn.978-3-8055-8782-2